Proposed U.S. tariffs expected to have minimal impact on CLS business
Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or "the Company") clarifies that the proposed U.S. tariffs are expected to have minimal impact on its total business, including operations in the United States.
This assessment is based on several key factors:
Established U.S. Presence
CLS's U.S. business is managed entirely through its wholly owned subsidiary, CLS Americas Inc., which oversees all imports and sales within the country. This setup gives CLS full control over its U.S. operations and limits exposure to external disruptions. The proposed U.S. tariffs will thus apply to CLS AB's priced products exported to CLS Americas Inc.
Clear Agreement on Tariff Management
CLS and its partners have included specific terms in their agreements that address how tariffs are to be managed between the companies, should they become a reality. This provides clarity and predictability, ensuring business continuity.
EU-Based Supply Chain
CLS's production and supply chain are based within the European Union, minimizing exposure to additional regions affected by proposed tariffs.
"Our structure is designed to be resilient. Thanks to our EU-based supply chain, U.S. operations run by our own subsidiary, and clear agreements with partners, we are well positioned to continue delivering on our growth plans," said Dan J. Mogren, CEO of CLS.
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-post: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG® Thermal Therapy System and ClearPoint Prism® Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se